500 related articles for article (PubMed ID: 30061443)
1. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
[TBL] [Abstract][Full Text] [Related]
2. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
Bernstein JA; Tyson C; Relan A; Adams P; Magar R
J Manag Care Spec Pharm; 2020 Feb; 26(2):203-210. PubMed ID: 31841366
[TBL] [Abstract][Full Text] [Related]
3. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency.
Zanichelli A; Mansi M; Azin GM; Wu MA; Periti G; Casazza G; Vacchini R; Suffritti C; Cicardi M
Allergy; 2015 Dec; 70(12):1553-8. PubMed ID: 26304015
[TBL] [Abstract][Full Text] [Related]
5. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency.
Zanichelli A; Azin GM; Wu MA; Suffritti C; Maggioni L; Caccia S; Perego F; Vacchini R; Cicardi M
J Allergy Clin Immunol Pract; 2017; 5(5):1307-1313. PubMed ID: 28284781
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.
Bork K; Bernstein JA; Machnig T; Craig TJ
J Emerg Med; 2016 Apr; 50(4):567-80.e1. PubMed ID: 26826769
[TBL] [Abstract][Full Text] [Related]
9. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
Grumach AS; Henriques MT; Bardou MLD; Pontarolli DA; Botha J; Correa M;
An Bras Dermatol; 2022; 97(4):448-457. PubMed ID: 35654647
[TBL] [Abstract][Full Text] [Related]
10. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.
Bork K; Staubach-Renz P; Hardt J
Orphanet J Rare Dis; 2019 Mar; 14(1):65. PubMed ID: 30866985
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
Farkas H; Kőhalmi KV; Visy B; Veszeli N; Varga L
J Allergy Clin Immunol Pract; 2020; 8(7):2379-2383. PubMed ID: 32198128
[TBL] [Abstract][Full Text] [Related]
12. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
[TBL] [Abstract][Full Text] [Related]
14. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
[TBL] [Abstract][Full Text] [Related]
15. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
[TBL] [Abstract][Full Text] [Related]
16. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
[TBL] [Abstract][Full Text] [Related]
17. Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
Toubi E; Kivity S; Graif Y; Reshef A; Botha J; Andresen I
Isr Med Assoc J; 2018 Apr; 20(4):227-232. PubMed ID: 29629730
[TBL] [Abstract][Full Text] [Related]
18. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.
Lumry WR; Martinez-Saguer I; Yang WH; Bernstein JA; Jacobs J; Moldovan D; Riedl MA; Johnston DT; Li HH; Tang Y; Schranz J; Lu P; Vardi M; Farkas H;
J Allergy Clin Immunol Pract; 2019; 7(5):1610-1618.e4. PubMed ID: 30682573
[TBL] [Abstract][Full Text] [Related]
19. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor.
Farkas H; Kőhalmi KV; Veszeli N; Zotter Z; Várnai K; Varga L
Allergy Asthma Proc; 2016; 37(2):164-70. PubMed ID: 26802388
[TBL] [Abstract][Full Text] [Related]
20. How satisfactory is on-demand icatibant from the patients' perspective in real life?
Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
